ERTMABTU
Experimental Radiotherapy for Malignant Brain Tumours
| Coordinatore | UNIVERSITAETSKLINIKUM FREIBURG
Organization address
address: HUGSTETTER STRASSE 49 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 100˙000 € |
| EC contributo | 100˙000 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2010-RG |
| Funding Scheme | MC-IRG |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-09-01 - 2014-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITAETSKLINIKUM FREIBURG
Organization address
address: HUGSTETTER STRASSE 49 contact info |
DE (FREIBURG) | coordinator | 100˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The aim of my project is to test two novel experimental radiotherapies which potentially can improve the quality life in patients with malignant brain tumours or with multiple brain metastases. Both methods are being developed at international synchrotron facilities. One of the techniques, microbeam radiation therapy (MRT), is already being studied by several groups and my work is focused on the assessment of adverse effects like memory deficits and bystander effects. Concept and equipment for the second technique, pencilbeam radiotherapy, have only recently been developed at the ESRF in France. Our team will be the first to obtain biological data and assist in developing the technique to a point where a valid assessment can be made regarding its feasibility for therapeutic approach in human patients. All tests will be conducted in well-validated small animal models for an advanced, highly malignant primary brain tumour and for multiple brain metastases from a mamma carcinoma. We will study the acute effects of the radiotherapy in short-term experiments as well as generate survival curves and behavioural data in long-term survivors. In order to document the efficacy of the experimental therapy we will also use a high-resolution synchrotron-based X-ray imaging technique, in which small groups of cells loaded with an X-ray opaque marker can be detected. The applicant for this project is one of the four patent holders for this method. The Marie Curie Reintegration Grant would help me to establish my own work group in Freiburg, thereby combining my previous research experience with the interests of the Department of Stereotactic Neurosurgery and the Laboratory of Molecular Neurosurgery, where I have been working since September 2009. The project also integrates research facilities in three European countries (Germany, France and Italy) as well as a collaboration with a radiobiology team from McMaster University in Hamilton, Canada.'